Compare CII & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CII | OPK |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 841.0M | 921.2M |
| IPO Year | N/A | 2011 |
| Metric | CII | OPK |
|---|---|---|
| Price | $23.30 | $1.23 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $1.55 |
| AVG Volume (30 Days) | 79.0K | ★ 2.3M |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | ★ 6.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.91 | $1.10 |
| 52 Week High | $26.17 | $1.60 |
| Indicator | CII | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 65.29 | 59.10 |
| Support Level | $23.11 | $1.12 |
| Resistance Level | $23.43 | $1.27 |
| Average True Range (ATR) | 0.41 | 0.04 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 85.17 | 82.41 |
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its investment objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. It may invest directly in such securities or synthetically through the use of derivatives. It also seeks to achieve its investment objective by employing a writing (selling) call and put options.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.